Literature DB >> 9789728

Mechanisms of drug-induced diarrhoea in the elderly.

R N Ratnaike1, T E Jones.   

Abstract

In the rapidly increasing elderly population, diarrhoea as a result of drug therapy is an important consideration. The elderly consume a disproportionately large number of drugs for multiple acute and chronic diseases. Drugs can compromise both immune and nonimmune responses. Aging decreases the quality and proportion of T cells which in turn reduces the production of secretory IgA, the primary immune response of the gut. Acid production in the stomach decreases with increasing age and this compromise its vital 'self-sterilising' function, thus increasing the risk of diarrhoea due to viral, bacterial and protozoal pathogens. Other nonimmune defence mechanisms include the motility of the small intestine and the host-protective commensal bacteria of the colon. Drug induced hypomotility may result in bacterial overgrowth, deconjugation of bile salts and diarrhoea. Less commonly, diarrhoea may occur due to hypermotility because of a cholinergic-like syndrome. In the colon the host-protective commensal bacteria provide a powerful defence against pathogens. Disruption of this commensal population by antibiotic therapy may result in Clostridium difficile supra-infection which causes diarrhoea through toxin production. This is especially important in the elderly patient on chemotherapy for malignancy and those with multiple diseases. The organism responds to vancomycin, metronidazole and bacitracin. Metronidazole is the suggested drug of choice, with vancomycin reserved for relapses. Drugs also cause diarrhoea by interfering with normal physiological processes. Drugs impair fluid absorption by activating adenylate cyclase within the small intestinal enterocyte which increases the level of cyclic AMP. This causes active secretion of Cl- and HCO3-, passive efflux of Na+, K+ and water and inhibition of Na+ and Cl- into the enterocyte. Examples of these drugs (secretagogues) are bisacodyl, misoprostol and chenodeoxycholic acid (used to dissolve cholesterol gallstones). Drugs may also affect a second mechanism that regulates water and electrolyte transport, the Na+, K+ exchange pump. The energy for this pump is provided by the ATPase mediated breakdown of ATP. ATPase may be inhibited by digoxin, auranofin, colchicine and olsalazine. A number of drugs cause osmotic diarrhoea including antacids containing magnesium trisilicate or hydroxide. Lactulose is being used increasingly in compensated liver disease to increase protein tolerance and prevent hepatic encephalopathy. Sorbitol, an osmotic laxative agent also used in some liquid pharmaceutical preparations, induces diarrhoea by virtue of its osmotic potential. Another mechanism by which drugs cause diarrhoea is by mucosal damage of the small and large bowel. In the small intestine mucosal damage causes diarrhoea and fat malabsorption, as may occur with neomycin and colchicine. In the colon, for example, gold salts and penicillamine cause colitis of varying severity. Though the causes of diarrhoea are diverse, a drug-associated aetiology should always be considered and actively sought and addressed to prevent the complications of dehydration, electrolyte imbalance and undernutrition.

Entities:  

Mesh:

Year:  1998        PMID: 9789728     DOI: 10.2165/00002512-199813030-00007

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  82 in total

1.  Effect of auranofin on absorptive processes in the rat small bowel.

Authors:  J Hardcastle; P T Hardcastle; D K Kelleher; L S Henderson; J D Fondacaro
Journal:  J Rheumatol       Date:  1986-06       Impact factor: 4.666

2.  Morphologic alterations associated with neomycin induced malabsorption.

Authors:  W O Dobbins; B A Herrero; C M Mansbach
Journal:  Am J Med Sci       Date:  1968-01       Impact factor: 2.378

3.  An investigation into Clostridium perfringens enterotoxin-associated diarrhoea.

Authors:  S C Samuel; P Hancock; D A Leigh
Journal:  J Hosp Infect       Date:  1991-07       Impact factor: 3.926

4.  Clostridium difficile diarrhoea: a highly infectious organism.

Authors:  G C Bennett; E Allen; P H Millard
Journal:  Age Ageing       Date:  1984-11       Impact factor: 10.668

Review 5.  Surgical aspects of Clostridium difficile colitis.

Authors:  A W Bradbury; S Barrett
Journal:  Br J Surg       Date:  1997-02       Impact factor: 6.939

6.  Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.

Authors:  F E Silverstein; D Y Graham; J R Senior; H W Davies; B J Struthers; R M Bittman; G S Geis
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

7.  Stereospecific actions of misoprostol on rat colonic electrolyte transport.

Authors:  S Won-Kim; J F Kachur; T S Gaginella
Journal:  Prostaglandins       Date:  1993-09

8.  Bacterial contamination of the small intestine is an important cause of occult malabsorption in the elderly.

Authors:  A McEvoy; J Dutton; O F James
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-17

9.  Auranofin (SK + F 39162) induced enterocolitis in rheumatoid arthritis. A case report.

Authors:  D Jarner; A M Nielsen
Journal:  Scand J Rheumatol       Date:  1983       Impact factor: 3.641

10.  Infection due to Clostridium difficile among elderly residents of a long-term-care facility.

Authors:  A E Simor; S L Yake; K Tsimidis
Journal:  Clin Infect Dis       Date:  1993-10       Impact factor: 9.079

View more
  18 in total

1.  Evaluating the patient with diarrhea: a case-based approach.

Authors:  Seth Sweetser
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

2.  Case report: adverse drug reactions in unrecognized kidney failure.

Authors:  Barbara Farrell; Kevin Pottie; William Hogg
Journal:  Can Fam Physician       Date:  2004-10       Impact factor: 3.275

Review 3.  Drug-induced diarrhea.

Authors:  Bincy Abraham; Joseph H Sellin
Journal:  Curr Gastroenterol Rep       Date:  2007-10

4.  Reducing fall risk while managing pain and insomnia: Addressing polypharmacy in an 81-year-old woman.

Authors:  Barbara Farrell; Salima Shamji; Nafisa Ingar
Journal:  Can Pharm J (Ott)       Date:  2013-11

5.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

6.  Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119.

Authors:  Ainhoa Nieto; Virneliz Fernández-Vega; Timothy P Spicer; Emmanuel Sturchler; Pramisha Adhikari; Nicole Kennedy; Sean Mandat; Peter Chase; Louis Scampavia; Thomas Bannister; Peter Hodder; Patricia H McDonald
Journal:  Assay Drug Dev Technol       Date:  2018-07       Impact factor: 1.738

Review 7.  Drug-induced diarrhoea.

Authors:  O Chassany; A Michaux; J F Bergmann
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

8.  Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.

Authors:  Changsuk Moon; Weiqiang Zhang; Aixia Ren; Kavisha Arora; Chandrima Sinha; Sunitha Yarlagadda; Koryse Woodrooffe; John D Schuetz; Koteswara Rao Valasani; Hugo R de Jonge; Shiva Kumar Shanmukhappa; Mohamed Tarek M Shata; Randal K Buddington; Kaushik Parthasarathi; Anjaparavanda P Naren
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

9.  [Antibiotic induced diarrhea and pseudomembranous colitis].

Authors:  C Greb; T Kalem; T Kälble
Journal:  Urologe A       Date:  2002-12-19       Impact factor: 0.639

Review 10.  Update on chronic diarrhea: a run-through for the clinician.

Authors:  Davinder K Sandhu; Christina Surawicz
Journal:  Curr Gastroenterol Rep       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.